Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
1 Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, CdMx, CP 01400, México City, Mexico. gonzalezduarte@aol.com.
2 Boston Medical Center, Boston, MA, USA.
3 University of Colorado, Denver, CO, USA.
4 Mayo Clinic, Rochester, MN, USA.
5 University of Münster, Münster, Germany.
6 Johns Hopkins University School of Medicine, Baltimore, MD, USA.
7 Hospital Universitário Clementino Fraga Filho-UFRJ, Rio de Janeiro, Brazil.
8 Kumamoto University Hospital, Kumamoto, Japan.
9 CHULN, Hospital de Santa Maria and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
10 University of Heidelberg, Heidelberg, Germany.
11 Hospital de Santo António, Centro Hospitalar Universitário Do Porto, Porto, Portugal.
12 AP-HP Université Paris Saclay, CHU Bicêtre, Le Kremlin Bicêtre, France.
13 Université de Lille, Lille, France.
14 Alnylam Pharmaceuticals, Cambridge, MA, USA.
15 AP-HP, Université Paris Saclay, CHU Bicêtre, Université Paris-Sud, INSERM 1195, Paris, France.